These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 28414749)

  • 1. Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B.
    Hause AM; Henke DM; Avadhanula V; Shaw CA; Tapia LI; Piedra PA
    PLoS One; 2017; 12(4):e0175792. PubMed ID: 28414749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
    Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
    Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of respiratory syncytial virus strain differences on pathogenesis and immunity.
    Melero JA; Moore ML
    Curr Top Microbiol Immunol; 2013; 372():59-82. PubMed ID: 24362684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative conformations of a major antigenic site on RSV F.
    Jones HG; Battles MB; Lin CC; Bianchi S; Corti D; McLellan JS
    PLoS Pathog; 2019 Jul; 15(7):e1007944. PubMed ID: 31306469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-center study to determine genetic variations in the fusion gene of respiratory syncytial virus (RSV) from children <2 years of age in the U.S.
    Adhikari B; Hassan F; Harrison CJ; Dien Bard J; Dunn J; Kehl S; Selvarangan R
    J Clin Virol; 2022 Sep; 154():105223. PubMed ID: 35792350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Removal of the N-Glycosylation Sequon at Position N116 Located in p27 of the Respiratory Syncytial Virus Fusion Protein Elicits Enhanced Antibody Responses after DNA Immunization.
    Leemans A; Boeren M; Van der Gucht W; Pintelon I; Roose K; Schepens B; Saelens X; Bailey D; Martinet W; Caljon G; Maes L; Cos P; Delputte P
    Viruses; 2018 Aug; 10(8):. PubMed ID: 30110893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino acid variation within the fusion protein of respiratory syncytial virus subtype A and B strains during annual epidemics in South Africa.
    Agenbach E; Tiemessen CT; Venter M
    Virus Genes; 2005 Mar; 30(2):267-78. PubMed ID: 15744582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles.
    Kwon YM; Lee Y; Kim KH; Jung YJ; Li Z; Jeeva S; Lee S; Moore ML; Kang SM
    Vaccine; 2019 Oct; 37(44):6656-6664. PubMed ID: 31542260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection.
    Qiao L; Zhang Y; Chai F; Tan Y; Huo C; Pan Z
    Antiviral Res; 2016 Jul; 131():131-40. PubMed ID: 27154395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
    Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
    J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein.
    Harshbarger W; Abeyrathne PD; Tian S; Huang Y; Chandramouli S; Bottomley MJ; Malito E
    MAbs; 2021; 13(1):1955812. PubMed ID: 34420474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective antigenic sites in respiratory syncytial virus G attachment protein outside the central conserved and cysteine noose domains.
    Lee J; Klenow L; Coyle EM; Golding H; Khurana S
    PLoS Pathog; 2018 Aug; 14(8):e1007262. PubMed ID: 30142227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variations in the fusion protein of respiratory syncytial virus isolated from children hospitalized with community-acquired pneumonia in China.
    Chen X; Xu B; Guo J; Li C; An S; Zhou Y; Chen A; Deng L; Fu Z; Zhu Y; Liu C; Xu L; Wang W; Shen K; Xie Z
    Sci Rep; 2018 Mar; 8(1):4491. PubMed ID: 29540836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
    J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
    Zhang L; Durr E; Galli JD; Cosmi S; Cejas PJ; Luo B; Touch S; Parmet P; Fridman A; Espeseth AS; Bett AJ
    Vaccine; 2018 Dec; 36(52):8119-8130. PubMed ID: 30340881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of respiratory syncytial virus fusion protein from clinical isolates of Korean children in palivizumab era, 2009-2015.
    Choi SH; Park KS; Kim YJ
    J Infect Chemother; 2019 Jul; 25(7):514-519. PubMed ID: 30885457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein of Respiratory Syncytial Virus Were Associated With Viral Clearance in Hematopoietic Cell Transplantation Adults.
    Ye X; Iwuchukwu OP; Avadhanula V; Aideyan LO; McBride TJ; Ferlic-Stark LL; Patel KD; Piedra FA; Shah DP; Chemaly RF; Piedra PA
    Front Immunol; 2019; 10():706. PubMed ID: 30984206
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.